EGFR and non-small cell lung carcinoma: As the patients enrolled in the current study were likely heterogeneous with respect to EGFR mutation status and mechanisms of resistance to prior EGFR TKI treatment, it is difficult to draw firm conclusions about the clinical activity of cabozantinib in EGFR mutant NSCLC.